Lead sponsor

Novo Nordisk A/S

445 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

445

Trials led

Active

1,349,366

Total enrollment

7,542

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1

168

Phase 2

Phase 3

149

Phase 4

Not applicable

Trials by status

Not yet recruiting

By invitation

Recruiting

Active, not recruiting

Completed

372

Terminated

Withdrawn

Unknown

Trials led

TrialKey I/E criterionPhaseStatusEnrollment

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data—not applicableUnknown600,000

A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World—not applicableCompleted285,327

SPOTLIGHT—not applicableBy invitation100,000

SCOREEstablished ASCVDnot applicableCompleted45,456

Weight Loss in Adults Using Semaglutide (Real-world Study)BMI ≥27not applicableRecruiting35,000

SCHOLAR—not applicableCompleted34,238

SELECTBMI ≥27 · Established CVDPh 3Completed17,604

Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants—not applicableCompleted9,999

SOULHbA1c 6.5-10%Ph 3Completed9,651

LEADER®—Ph 3Completed9,341

REDEFINE 3HbA1c 6.5-10%Ph 3Active, not recruiting7,101

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)—not applicableBy invitation6,750

HF-POLARIS—Ph 3Not yet recruiting5,610

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes—not applicableCompleted4,121

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes—Ph 3Completed3,731

FLOWHbA1c ≤10%Ph 3Completed3,533

SELECT-LIFE—not applicableCompleted3,439

REDEFINE 1BMI ≥30Ph 3Active, not recruiting3,400

SUSTAIN™ 6—Ph 3Completed3,297

Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®—not applicableCompleted3,217

PIONEER 6—Ph 3Completed3,183

EVIDENCE—not applicableCompleted3,152

REIMAGINE 2BMI ≥25Ph 3Completed2,734

OUTSTEP-1—not applicableBy invitation2,546

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightBMI ≥35Ph 3Recruiting2,500

SUSTAIN 11HbA1c ≥7.5%Ph 3Completed2,274

LIRA-PRIMEHbA1c 7.5-9%Ph 4Completed1,991

STEP 1BMI ≥30Ph 3Completed1,961

PIONEER 3HbA1c 7-10.5%Ph 3Completed1,864

EVOKE—Ph 3Completed1,840

EVOKE Plus—Ph 3Completed1,840

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice—not applicableCompleted1,788

DUAL™ IHbA1c 7-10%Ph 3Completed1,663

PIONEER PLUSBMI ≥25Ph 3Completed1,606

FOCUSHbA1c 7-10%Ph 3Active, not recruiting1,500

PIONEER 12HbA1c 7-10.5%Ph 3Completed1,441

STEP UPBMI ≥30Ph 3Completed1,407

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight—Ph 3Not yet recruiting1,400

ADJUNCT ONE™HbA1c 7-10%Ph 3Completed1,398

Lead-In—not applicableCompleted1,386

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2—not applicableCompleted1,344

COMBINE 1—Ph 3Completed1,291

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial—Ph 4Completed1,278

PILLAR—not applicableBy invitation1,250

SUSTAIN™ 2HbA1c 7-10.5%Ph 3Completed1,231

STEP 2BMI ≥27Ph 3Completed1,210

ESSENCE—Ph 3Active, not recruiting1,205

SUSTAIN 7HbA1c 7-10.5%Ph 3Completed1,201

REDEFINE 2HbA1c 7-10%Ph 3Completed1,200

AMAZE 1—Ph 3Recruiting1,150

A Study to Evaluate the Safety of Exposure to Wegovy During PregnancyBMI ≥30not applicableBy invitation1,139

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)—not applicableCompleted1,092

LEAD-2HbA1c 7-11%Ph 3Completed1,091

SUSTAIN™ 4HbA1c 7-10%Ph 3Completed1,089

Special Use - Results Surveillance on Long-term Use With Wegovy®BMI ≥27not applicableActive, not recruiting1,071

A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden—not applicableCompleted1,059

Lead-Ph—not applicableCompleted1,056

LEAD-1BMI ≤45Ph 3Completed1,041

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorBMI ≥30Ph 3Completed1,024

REIMAGINE 5BMI ≥30Ph 3Active, not recruiting1,023

REALYSEHbA1c ≥7%Ph 4Completed1,020

DUAL™ VIIIBMI ≥20Ph 3Completed1,012

AMAZE 8HbA1c 7-10%Ph 3Not yet recruiting1,000

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 DiabetesHbA1c 7-10%Ph 3Completed987

SUSTAIN FORTEHbA1c 8-10%Ph 3Completed961

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusBMI ≥30Ph 2Completed957

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe—not applicableCompleted952

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 DiabetesBMI ≤45Ph 3Completed929

STEP 4BMI ≥30Ph 3Completed902

SUSTAINHbA1c 7-10.5%Ph 3Completed868

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - DiabetesBMI ≥27Ph 3Completed846

A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea—not applicableBy invitation840

VIEW-IranHbA1c ≤12%not applicableCompleted839

ADJUNCT TWO™HbA1c 7-10%Ph 3Completed835

PIONEER 2HbA1c 7-10.5%Ph 3Completed822

DUAL™ I JapanHbA1c 7-11%Ph 3Completed819

SUSTAIN™ 3HbA1c 7-10.5%Ph 3Completed813

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightBMI ≥30Ph 3Completed809

STRIDE—Ph 3Completed792

SURE GERMANYHbA1c ≤12%not applicableCompleted789

SUSTAIN 8HbA1c 7-10.5%Ph 3Completed788

A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.—not applicableCompleted758

Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea—not applicableCompleted750

LEAD-3BMI ≤45Ph 3Terminated746

PIONEER 8HbA1c 7-9.5%Ph 3Completed731

A Study to Evaluate Safety of Exposure to Wegovy During PregnancyFemalenot applicableBy invitation728

DUAL™ I ChinaHbA1c 7-10%Ph 3Completed720

PIONEER 4HbA1c 7-9.5%Ph 3Completed711

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 DiabetesBMI 25-40Ph 2Completed706

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.—Ph 2Completed706

PIONEER 1HbA1c 7-9.5%Ph 3Completed703

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)—Ph 2Completed698

COMBINE 2HbA1c 7-10%Ph 3Completed683

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)BMI ≤40Ph 3Completed679

OASIS 1—Ph 3Completed667

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes MellitusBMI ≤45Ph 3Completed665

PIONEER REAL—not applicableCompleted650

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.HbA1c 7.5-10%Ph 3Completed635

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 DiabetesHbA1c 7-9.5%Ph 2Completed632

AMAZE 2HbA1c 7-10%Ph 3Recruiting630

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboBMI ≥27Ph 2Completed626

STEP HFpEF DMBMI ≥30Ph 3Completed617

STEP 3—Ph 3Completed611

A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus—not applicableCompleted611

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termBMI ≥30Ph 3Active, not recruiting609

SUSTAIN™HbA1c 7-10.5%Ph 3Completed601

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaFemalenot applicableNot yet recruiting600

AMAZE 12—Ph 3Recruiting600

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea—not applicableBy invitation600

LEAD-5BMI ≤45Ph 3Completed584

SURE ITALYHbA1c ≤12%not applicableCompleted581

SUSTAIN 10HbA1c 7-11%Ph 3Completed577

LEAD-4BMI ≤45Ph 3Completed576

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)HbA1c 7-10%Ph 3Completed573

The Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesBMI ≥30Ph 2Completed564

DUAL™ VHbA1c 7-10%Ph 3Completed557

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy PeopleBMI 21-32Ph 1Completed546

STEP-HFpEFBMI ≥30Ph 3Completed529

SURE FRANCEHbA1c ≤12%not applicableCompleted521

PIONEER 11HbA1c 7-10%Ph 3Completed521

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightBMI ≥30Ph 3Completed512

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes MellitusHbA1c 7-10%Ph 3Completed506

PIONEER 7HbA1c 7.5-9.5%Ph 3Completed504

WEgovy Real World Assessment of Weight Loss in Korea—not applicableBy invitation500

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight LossAge 12-15Ph 4Active, not recruiting500

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 DiabetesBMI ≥25Ph 2Completed500

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America—Ph 4Completed500

COMBINE 4HbA1c ≥8%Ph 3Completed485

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in HungaryHbA1c ≥7%not applicableRecruiting470

LEAD-6BMI ≤45Ph 3Completed467

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease—Ph 2Recruiting465

PIONEER REAL—not applicableCompleted465

SURE CANADAHbA1c ≤12%not applicableCompleted462

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight—Ph 3Recruiting460

PIONEER REAL—not applicableCompleted458

PIONEER 10HbA1c 7-10.5%Ph 3Completed458

DUAL™ II China—Ph 3Completed453

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 DiabetesBMI 20-45Ph 3Completed451

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesBMI ≤50Ph 2Completed448

DUAL™ IIIBMI ≤40Ph 3Completed438

DUAL™IVHbA1c 7-9%Ph 3Completed435

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - MaintenanceBMI 27-30Ph 3Completed422

DUALTM IXBMI ≥20Ph 3Completed420

DUAL™ VIHbA1c 7-10%Ph 3Completed420

A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and LiraglutideHbA1c 7-10%Ph 2Completed415

BEGIN™—Ph 3Completed413

DUAL™ IIHbA1c 7.5-10%Ph 3Completed413

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee OsteoarthritisBMI ≥30Ph 3Completed407

LIRA-SWITCH™BMI ≥20Ph 4Completed407

LIRA-LIXI™BMI ≥20Ph 4Completed404

STEP 6HbA1c 7-10%Ph 3Completed401

A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesBMI 25-39.9Ph 2Not yet recruiting400

AMAZE 6—Ph 3Recruiting400

AMAZE 5—Ph 3Recruiting400

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity—Ph 3Active, not recruiting400

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesBMI ≤35Ph 3Completed400

SUSTAIN™ 5HbA1c 7-10%Ph 3Completed397

SCALE™ InsulinBMI ≥27Ph 3Completed396

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 DiabetesHbA1c 7-10.5%Ph 3Completed388

PIONEER REAL—not applicableCompleted388

SUSTAIN™1HbA1c 7-10%Ph 3Completed388

A Research Study Looking at New Protein-based Tablets in Healthy Male ParticipantsBMI 20-29.9Ph 1Completed384

STEP7HbA1c 7-10%Ph 3Completed375

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.HbA1c ≥8%Ph 3Completed373

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 DiabetesHbA1c 7-10%Ph 4Completed368

Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD AloneBMI ≤40Ph 3Completed363

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep ApnoeaBMI ≥30Ph 3Completed359

A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in ItalyHbA1c ≥3%not applicableCompleted359

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightBMI ≥27Ph 2Completed354

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment IntensificationHbA1c 7.5-10%Ph 3Completed346

LIRA-Ramadan™BMI ≥20Ph 4Completed343

STEP 8BMI ≥30Ph 3Completed338

PIONEER REAL—not applicableCompleted336

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity—Ph 2Recruiting333

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)HbA1c ≤12%not applicableCompleted333

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightBMI ≥27Ph 3Completed331

RENEW 2BMI ≥27Ph 3Active, not recruiting330

PIONEER 5HbA1c 7-9.5%Ph 3Completed324

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.—Ph 2Completed320

In-market Utilisation of Liraglutide Used for Weight Management in Europe—not applicableCompleted316

MIRAGE—not applicableCompleted314

SUSTAIN™HbA1c 6.5-9.5%Ph 3Completed308

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function—Ph 2Completed308

OASIS 4—Ph 3Completed307

STEP 5—Ph 3Completed304

A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment—not applicableCompleted304

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.HbA1c 7-9.5%Ph 3Completed303

SUSTAIN 9HbA1c 7-10%Ph 3Completed302

AMAZE 4—Ph 3Recruiting300

AMAZE 3—Ph 3Recruiting300

RENEW 1BMI ≥30Ph 3Active, not recruiting300

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight—Ph 3Completed300

INTENSIFYHbA1c ≤12%not applicableCompleted300

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.—not applicableCompleted300

REDEFINE 6BMI ≥30Ph 3Completed300

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesHbA1c 7.5-10%Ph 2Completed299

DOORSHbA1c ≥7.5%not applicableCompleted291

Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy PeopleBMI 21-29.9Ph 1Completed290

O-SEMA-Fast—not applicableCompleted288

SCALE™ IBT—Ph 3Completed282

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal ImpairmentBMI 20-45Ph 3Completed279

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide TabletsBMI 20-29.9Ph 1Completed278

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide TabletsBMI 20-29.9Ph 1Completed274

REIMAGINE 3BMI ≥25Ph 3Completed274

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesHbA1c 7-10%Ph 2Recruiting270

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease—Ph 2Completed270

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in SwitzerlandBMI ≥35not applicableCompleted269

A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 DiabetesHbA1c 7-10.5%Ph 3Active, not recruiting264

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 DiabetesBMI ≤35Ph 3Completed264

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy ParticipantsBMI 23-34.9Ph 1Completed264

Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 DiabetesBMI ≤45Ph 3Completed257

ROOTS—not applicableCompleted254

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With ObesityBMI ≥30Ph 3Completed251

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and OverweightBMI ≥27Ph 2Completed245

GOAL—not applicableCompleted244

PIONEER 9HbA1c 6.5-9.5%Ph 3Completed243

STEP12BMI ≥24Ph 3Completed242

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityBMI 27-34.9Ph 1Not yet recruiting234

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity—Ph 2Not yet recruiting230

SURE SPAINHbA1c ≤12%not applicableCompleted230

Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 DiabetesBMI ≤30Ph 2Completed226

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic AgentBMI 27-42Ph 2Completed223

SURE NLHbA1c ≤12%not applicableCompleted218

SURE UKHbA1c ≤12%not applicableCompleted215

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)HbA1c ≤12%not applicableCompleted215

STEP YoungHbA1c ≤10%Ph 3Active, not recruiting210

DUAL™ II JapanBMI ≥23Ph 3Completed210

REALISEDHbA1c ≤12%not applicableCompleted209

STEP 10BMI ≥30Ph 3Completed207

OASIS 2BMI ≥27Ph 3Completed201

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or ObesityHbA1c ≤10%Ph 3Completed201

OASIS 3HbA1c 7-10%Ph 3Completed200

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity—Ph 4Completed200

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 DiabetesHbA1c 7.5-10%Ph 2Completed196

PIONEER REAL—not applicableCompleted194

REIMAGINE 1BMI ≥23Ph 3Completed189

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice—not applicableCompleted187

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With ObesityBMI 25-39.9Ph 1Completed187

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.BMI 27-34.9Ph 1Recruiting177

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesHbA1c ≤10%Ph 2Completed177

SPIRIT—not applicableCompleted175

Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male SubjectsBMI 20-30Ph 1Completed170

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy SubjectsBMI 20-30Ph 1Completed168

A Study of How CagriSema Works on Appetite in People With Excess Body WeightBMI 18.5-24.9Ph 1Completed164

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male SubjectsBMI 27-35Ph 1Completed163

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.Healthy volunteersPh 1Completed161

Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male SubjectsBMI 18.5-30Ph 1Completed161

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesBMI 25-45 · Established CVDPh 1Completed158

A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different TimesBMI 20-29.9Ph 1Completed156

PIONEER REAL—not applicableCompleted155

A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One TabletBMI 20-29.9Ph 1Completed152

First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With DiabetesBMI 20-29.9Ph 1Completed152

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With ObesityBMI ≥25Ph 3Completed150

A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 DiabetesHbA1c 7.5-10.5%Ph 3Completed148

PIONEER REAL—not applicableCompleted145

Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 DiabetesBMI 25-40Ph 2Completed145

RAMBOBMI ≥30Ph 1Recruiting144

A Research Study on How NNC0487-0111 Works in People With Overweight or ObesityBMI 25-34.9Ph 1Completed144

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyBMI ≥25Ph 2Active, not recruiting142

Ellipse™HbA1c 7-11%Ph 3Completed135

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or ObesityBMI 27-44.9Ph 1Completed134

A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or ObesityBMI 27-39.9Ph 1Completed133

PIONEER TEENSHbA1c 6.5-11%Ph 3Completed132

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the SkinBMI 27-39.9Ph 2Completed125

A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy ParticipantsBMI 18.5-29.9Ph 1Completed121

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IIIBMI 22-31.9Ph 1Completed121

A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity—Ph 1Recruiting120

A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity—Ph 1Recruiting120

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With ObesityBMI 30-45Ph 2Completed120

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events—Ph 1Not yet recruiting114

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once WeeklyBMI 20-29.9Ph 1Completed113

A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection PensBMI 25-34.9Ph 1Completed111

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin—Ph 2Completed108

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy ParticipantsBMI 23-29.9Ph 1Completed107

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 DiabetesBMI ≤30Ph 1Completed107

REMODELeGFR ≥30Ph 3Completed106

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database—not applicableCompleted105

Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy MenBMI 20-29.9Ph 1Completed105

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide scBMI ≥25Ph 4Completed104

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 DiabetesHbA1c 7.5-10%Ph 4Completed104

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and ObesityBMI ≥25Ph 2Completed104

A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and ObesityBMI ≥25Ph 2Completed103

A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 DiabetesBMI ≤39.9 · Established CVDPh 1Completed101

RASMUS—Ph 1Recruiting100

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseFemalePh 1Recruiting100

WeGoReal—not applicableTerminated100

PIONEER REAL—not applicableCompleted99

A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 DiabetesBMI 22-35Ph 1Active, not recruiting96

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male SubjectsBMI 21-30Ph 1Completed96

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or OverweightBMI 25-39.9Ph 1Completed96

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or ObeseBMI 27-39.9Ph 1Completed96

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesBMI ≥27Ph 2Completed92

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IVBMI 22-31.9Ph 1Completed90

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or ObeseBMI 25-34.9Ph 1Completed88

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 DiabetesBMI 20-35Ph 1Completed87

Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian SubjectsBMI 18.5-24.9Ph 1Completed84

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes—Ph 1Completed82

REIMAGINEYOUNGHbA1c 6.5-11%Ph 3Not yet recruiting80

Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 DiabetesHbA1c 6.5-9.5%Ph 1Recruiting80

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet—Ph 1Recruiting80

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityAge 6-12Ph 3Active, not recruiting78

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy SubjectsBMI 18.5-29.9Ph 1Completed78

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)—Ph 1Recruiting75

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes TreatmentBMI ≤40Ph 4Completed75

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With ObesityBMI 30-45Ph 1Completed72

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal FunctionBMI 18.5-40Ph 1Completed71

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver DamageBMI ≥27Ph 2Completed71

Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pHBMI 18-30Ph 1Completed70

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection ToolsBMI 20-29.9Ph 1Completed68

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection PensBMI 25-34.9Ph 1Completed68

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or ObesityBMI 27-34.9Ph 1Completed68

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the LiverBMI 25-40Ph 1Completed67

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With ObesityBMI 20-39.9Ph 1Completed66

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus—not applicableCompleted64

Effect of Liraglutide on Heart Frequency in Healthy VolunteersBMI 20-29Ph 1Completed64

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or ObesityBMI 25-34.9Ph 1Active, not recruiting63

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightBMI ≥27Ph 1Completed62

Effect of Renal Impairment on the Pharmacokinetics of NN9535BMI ≤40Ph 1Completed62

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With ObesityBMI 30-45Ph 1Completed60

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male SubjectsBMI ≤35Ph 1Completed58

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or ObesityBMI 27-39.9Ph 1Completed57

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic ImpairmentBMI 18.5-40Ph 1Completed56

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeBMI ≥30Ph 3Completed56

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or ObesityBMI 25-34.9Ph 1Completed56

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.BMI 18.5-39.9Ph 1Completed55

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsBMI 20-35Ph 1Completed54

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)BMI 20-29.9Ph 1Completed54

Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy SubjectsBMI 18.5-29.9Ph 1Completed54

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate FormulationsBMI ≥25Ph 1Completed53

A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.BMI ≥27Ph 1Completed52

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy SubjectsBMI 20-29.9Ph 1Completed52

A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightBMI 27-34.9Ph 1Not yet recruiting50

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy SubjectsBMI 18.5-27Ph 1Completed50

PIONEER REAL—not applicableCompleted50

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes MellitusBMI ≤40Ph 3Completed49

A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese VolunteersBMI 30-40Ph 1Completed49

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian SubjectsBMI 20-25Ph 1Completed48

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After MenopauseBMI 27-39.9Ph 1Completed47

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine—Ph 1Completed46

The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 DiabetesBMI 20-28Ph 1Completed45

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.BMI 20-29.9Ph 1Completed45

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian SubjectsBMI 20-25Ph 1Completed44

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionBMI 18.5-40Ph 1Completed44

A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male SubjectsBMI 18-27Ph 1Completed44

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become PregnantBMI 25-39.9Ph 1Completed43

Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 DiabetesBMI 27-40Ph 1Completed43

Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 DiabetesBMI 18.5-35Ph 1Completed43

Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of SemaglutideBMI 20-30Ph 1Completed42

A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney FunctionBMI 20-39.9Ph 1Completed42

A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney FunctionBMI 18.5-39.9Ph 1Completed42

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney FunctionBMI 20-39.9Ph 1Completed42

A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian MenBMI 23-34.9Ph 1Completed42

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy SubjectsBMI 20-29.9Ph 1Completed41

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityBMI 27-39.9Ph 1Completed40

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.BMI 20-29.9Ph 1Completed40

A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 DiabetesBMI 20-35Ph 1Completed38

To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or PlaceboBMI 19-27Ph 1Completed37

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or ObeseBMI 27-39.9Ph 1Completed37

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With ObesityBMI 25-34.9Ph 1Completed36

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese SubjectsBMI 20-24.9Ph 1Completed36

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.BMI 24-34.9Ph 1Completed36

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney FunctionBMI 20-39.9Ph 1Completed36

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function—Ph 1Not yet recruiting35

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 DiabetesBMI ≥27Ph 2Completed35

A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.BMI 18.5-29.9Ph 1Completed34

Safety and Tolerability of Liraglutide in Healthy Male VolunteersBMI 20-27Ph 1Completed34

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightBMI 27-39.9Ph 1Completed34

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function—Ph 1Completed33

A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver FunctionBMI 18.5-39.9Ph 1Completed33

Examination of the Effects of Liraglutide on the Mode of Action of Insulin DetemirBMI ≤45Ph 1Completed33

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the BodyBMI 18.5-39.9Ph 1Completed32

Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male VolunteersBMI 20-30Ph 1Completed32

Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy VolunteersBMI 18-30Ph 1Completed32

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese VolunteersBMI 18-27Ph 1Completed32

A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are ChineseBMI 20-24.9Ph 1Completed32

Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy SubjectsBMI 20-29.9Ph 1Completed32

Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy SubjectsBMI 20-29.9Ph 1Completed31

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy SubjectsBMI 20-35Ph 1Completed31

Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become PregnantBMI 25-39.9Ph 1Completed31

DUAL™—Ph 3Completed31

Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function—Ph 1Completed30

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or TogetherHbA1c 6-8.5%Ph 1Completed30

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With PlaceboBMI 30-45Ph 1Completed30

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or ObesityBMI 27-34.9Ph 1Terminated29

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral DosingBMI 24-34.9Ph 1Completed29

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of SemaglutideBMI 20-27Ph 1Completed28

A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing ProcessesBMI 18.5-30Ph 1Completed28

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male SubjectsBMI 18.5-30Ph 1Completed27

A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After MenopauseBMI 20-29.9Ph 1Completed27

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican PatientsBMI ≥30not applicableCompleted27

A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal FemalesBMI 20-29.9Ph 1Completed25

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese SubjectsBMI 19-24Ph 1Completed24

A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese MenBMI 23-34.9Ph 1Completed24

A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With ObesityBMI 20-39.9Ph 1Completed24

Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 DiabetesBMI 19-30Ph 1Completed24

Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectorsBMI ≥27Ph 1Completed24

Safety and Tolerability of Liraglutide in Healthy Japanese VolunteersBMI 18-27Ph 1Completed24

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 YearsAge 7-11Ph 1Completed24

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese MenBMI 20-24.9Ph 1Completed24

Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver FunctionBMI 18.5-40Ph 1Completed24

Comparison of Three Liraglutide Formulations in Healthy VolunteersBMI 18-27Ph 1Completed24

Safety and Tolerability of Liraglutide in Healthy Japanese Male VolunteersBMI 18-27Ph 1Completed24

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese MenBMI 20-27.9Ph 1Completed24

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy SubjectsBMI 23-30Ph 1Completed24

Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy SubjectsBMI 20-27Ph 1Completed24

Safety and Tolerability of NN9068 in Healthy Male VolunteersBMI 18-27Ph 1Completed24

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease—Ph 3Completed23

Bioequivalence of Two Liraglutide Formulations in Healthy VolunteersBMI 18-27Ph 1Completed22

Comparison of Two Liraglutide Formulations in Healthy SubjectsBMI 18-27Ph 1Completed22

Comparison of Two Liraglutide Formulations in Healthy VolunteersBMI 18-27Ph 1Completed22

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese MenMalePh 1Completed22

Safety of Liraglutide in Pediatric Patients With Type 2 DiabetesHbA1c 6.5-11%Ph 1Completed21

A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy SubjectsBMI 18.5-29.9Ph 1Completed21

Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal WomenBMI 18-30Ph 1Completed21

A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 YearsAge 12-17Ph 1Completed21

Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy VolunteersBMI 18.5-27.5Ph 1Completed21

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) DoseBMI 20-29.9Ph 1Completed20

A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or TogetherBMI 18.5-34.9Ph 1Completed20

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body WeightBMI 24-39.9Ph 1Completed20

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control GroupBMI 24-35Ph 1Completed20

A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 DiabeticsBMI 18.5-40Ph 1Completed20

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes—Ph 1Completed19

Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 DiabetesBMI 18.5-40Ph 1Completed18

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityBMI 27-39.9Ph 1Completed18

A Clinical Trial Looking at the Comparability of 2 Different Forms of SemaglutideBMI 25-34.9Ph 1Completed18

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes—Ph 2Completed17

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy PeopleBMI 20-29.9Ph 1Completed16

Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 DiabetesBMI 18.5-30Ph 1Completed15

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 DiabetesBMI 20-38Ph 1Completed15

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide TabletsBMI 20-32.4Ph 1Completed14

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 DiabetesBMI 24-35Ph 1Completed11

Metabolism and Excretion of Liraglutide in Healthy Male VolunteersBMI 20-27Ph 1Completed7

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male SubjectsBMI 20-30Ph 1Completed7

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation—Ph 2Terminated3

PIONEER REAL—not applicableWithdrawnnot disclosed

INSPIRE Turkey—not applicableWithdrawnnot disclosed

GLIDE—not applicableWithdrawnnot disclosed

Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India—not applicableWithdrawnnot disclosed

PIONEER STARTHbA1c 7-9.5%Ph 3Withdrawnnot disclosed

SUSTAIN SWITCHHbA1c 6.5-10%Ph 3Withdrawnnot disclosed

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 DiabetesBMI ≥25Ph 3Withdrawnnot disclosed

A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 DiabetesHbA1c ≤12%not applicableWithdrawnnot disclosed